Triplet Therapeutics
Manufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1 Kendall Sq Ste 14201, Cambridge, Massa...Website
www.triplettx.comRevenue
$6.5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Triplet Therapeutics
Founded in 2018, Triplet Therapeutics is a biotechnology company focused on developing treatments for expansion disorders. They are headquartered in Cambridge, Massachusetts.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Triplet Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Triplet Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once Triplet Therapeutics has new funding data
Click to see if Triplet Therapeutics had a recent Job posting/layoffs
Check out if Triplet Therapeutics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Check if Triplet Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Triplet Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Triplet Therapeutics
Product Launch: Get notified when Triplet Therapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Triplet Therapeutics
Find 3 more new buyers
Compare Similar Companies to Triplet Therapeutics
Compare insights from companies similar to Triplet Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Triplet Therapeutics
$6.5M
11-50
Private
-
2018
N/A
Company Profile Activity
Activity Insights
Triplet Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Triplet Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Triplet Therapeutics.
Triplet Therapeutics Tech Stack
A closer look at the technologies used by Triplet Therapeutics
Most Recent Scoops
Left Company
Executive Move
Left Company
Executive Move
Funding
Funding
Funding
Triplet Therapeutics News & Media
Triplet Therapeutics to Present at Upcoming Events
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Triplet Therapeutics, Inc., a biotechnology company leveraging insights from the human genetics of repeat expansion disorders (REDs), today announced that Nessan Bermingham, Ph.D., Triplet’s chief executive officer, president and founder, will present at the following upcoming virtual events: Stifel 2021 CNS Day, Thursday, April 1, 2021 fireside chat at 2:00 p.m. ET; Guggenheim Healthcare Talks 2021 | Genomic Medicines & Rare Disease, Thursday, April 1, 20Triplet Therapeutics Appoints Kathy Biberstein, J.D., and Stephen Webster to its Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Triplet Therapeutics, Inc., a biotechnology company leveraging insights from the human genetics of repeat expansion disorders (REDs), today announced the appointments of Kathy Biberstein, J.D., and Stephen Webster to its board of directors. Ms. Biberstein brings extensive legal, policy and operations expertise in the global biopharma industry, most recently serving as Executive Vice President, Chief Administrative & Legal Officer, Chief Compliance & RiTriplet Therapeutics to Present at Stifel Virtual Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Triplet Therapeutics, Inc., a biotechnology company leveraging insights from the human genetics of repeat expansion disorders (REDs), today announced that Nessan Bermingham, Ph.D., Triplet’s chief executive officer, president, and founder, will present at the Stifel Virtual Healthcare Conference taking place November 16-18, 2020. Dr. Bermingham will discuss Triplet’s recent activities, including: The company’s selection of its first clinical candidate from itsTriplet Therapeutics Completes Enrollment of SHIELD HD Natural History Study of Huntington’s Disease
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Triplet Therapeutics, Inc., a biotechnology company leveraging insights from the human genetics of repeat expansion disorders (REDs), today announced it has achieved its target enrollment in the SHIELD HD natural history study of Huntington’s disease (HD). The study, initiated in May of this year, exceeded its target enrollment of 60 Huntington’s disease gene expansion carriers ahead of schedule. It will now expand to secure further enrollment from European si
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Triplet Therapeutics
Sign Up For FreeTo access detailed company insights
Founded in 2018, Triplet Therapeutics is a biotechnology company focused on developing treatments for expansion disorders. They are headquartered in Cambridge, Massachusetts.... Read More
